Svetlana Gataullina

Title: Svetlana Gataullina: Innovator in NMDA Receptor Modulation

Introduction

Svetlana Gataullina is a prominent inventor based in Antony, France. She has made significant contributions to the field of neuroscience through her innovative research and development of NMDA receptor modulators. Her work focuses on the prevention and treatment of diseases involving the central nervous system.

Latest Patents

Svetlana holds a patent for NMDA receptor modulators, compositions comprising the same, and the use of these compounds in the treatment of diseases involving the central nervous system. This invention relates specifically to compounds of 1-(indol-3-yl)-3-hydroxy-3-(2-oxo-2-ethyl)-indol-2-ones type, which are utilized as drugs. The pharmaceutical compositions developed from these compounds aim to prevent or treat various conditions, including severe/resistant epilepsy, cognitive disorders such as autism, strokes, schizophrenia, and degenerative diseases like Parkinson's and Alzheimer's disease. Her patent addresses a critical need in the medical community for effective treatments for these challenging conditions. She has 1 patent to her name.

Career Highlights

Svetlana is currently associated with Adpuerivitam, where she continues her research and development efforts. Her work has garnered attention for its potential impact on treating complex neurological disorders.

Collaborations

Svetlana collaborates with notable colleagues, including Mouad Alami and Jean Daniel Brion, who contribute to her research initiatives and help advance her innovative projects.

Conclusion

Svetlana Gataullina is a trailblazer in the field of NMDA receptor modulation, with her groundbreaking patent paving the way for new treatments for central nervous system diseases. Her contributions are vital to the ongoing efforts to improve the lives of those affected by these conditions.